WO2024003078A1 - Composition ophtalmique sans conservateur comprenant un analogue de prostaglandine - Google Patents

Composition ophtalmique sans conservateur comprenant un analogue de prostaglandine Download PDF

Info

Publication number
WO2024003078A1
WO2024003078A1 PCT/EP2023/067517 EP2023067517W WO2024003078A1 WO 2024003078 A1 WO2024003078 A1 WO 2024003078A1 EP 2023067517 W EP2023067517 W EP 2023067517W WO 2024003078 A1 WO2024003078 A1 WO 2024003078A1
Authority
WO
WIPO (PCT)
Prior art keywords
ophthalmic composition
preservative
composition
use according
free
Prior art date
Application number
PCT/EP2023/067517
Other languages
English (en)
Inventor
Marzena ROLA-LASEK
Jakub ZARCZUK
Katarzyna Malik
Original Assignee
Warszawskie Zaklady Farmaceutyczne Polfa Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawskie Zaklady Farmaceutyczne Polfa Sa filed Critical Warszawskie Zaklady Farmaceutyczne Polfa Sa
Publication of WO2024003078A1 publication Critical patent/WO2024003078A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Definitions

  • the present invention relates to a preservative-free ophthalmic composition
  • a preservative-free ophthalmic composition comprising a prostaglandin analogue as active ingredient, which is contained in a multidose dispensing device, and which remains microbiologically acceptable for a long period during use.
  • Glaucoma is a blinding disease characterized by the death of retinal ganglion cells and their axons and is a major cause of irreversible blindness worldwide.
  • An elevated intraocular pressure (IOP) is the main risk factor for disease progression, and, therefore, lowering IOP is the standard strategy for glaucoma therapy.
  • prostaglandin F2a analogues particularly, latanoprost, travoprost, bimatoprost, and tafluprost, which have high lOP-lowering efficacy, allowing for once-daily dosage, and are now the first-line agents representing the standard of care for combating ocular hypertension (Klimko PG et al., Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma, Br. J. Pharmacol., 2019, 176(8), 1051 -1058).
  • the ophthalmic solutions are usually available as multi-dose bottles, providing medication for several months in one single package.
  • the inclusion of antimicrobial preservative in the solutions is required, frequently, the quaternary ammonium benzalkonium chloride (BAK).
  • BAK quaternary ammonium benzalkonium chloride
  • BAK may cause or enhance harmful consequences on the ocular surface, including the tear film, cornea and conjunctiva, particularly after prolonged use, as is the case of anti-glaucoma medications (Baudouin eta!., Preservatives in eyedrops: The good, the bad and the ugly, Prog. Retin. Eye Res., 2010, 29, 312-334). Due to those well-documented BAK-related side effects, a need for preservative-free topical antiglaucoma medications has arisen and, consequently, several preservative-free ophthalmic dosage forms for prostaglandin analogues have been developed.
  • preservative-free multiple-dose (PFMD) dosage forms in the form of bottles containing enough ophthalmic solution for several uses, are the optimal option for both avoiding the adverse effects of the preservative and also providing a more economical and more convenient form for the patients for the long-term treatment of glaucoma.
  • PFMD preservative-free multiple-dose
  • PFMD systems For avoiding microbiological contamination in PFMD systems, several closure devices have been developed, which, according to different strategies, set up a barrier to prevent bacteria from entering into the container.
  • Different systems are available, for example, those based on pump systems (such as COMOD® and 3K® systems) or those based on the use of non-return valves combined with filters for the compensating air entering into the container (such as Novelia® and OSD®) (Yoon et al., Packaging Development: Multi-dose container closure for preservative free products, extractable/leachables from packaging, new technologies, in: Neervannan, S., Kompella, U.B. (eds) Ophthalmic Product Development. AAPS Advances in the Pharmaceutical Sciences Series, vol 37. Springer, Ophthalmic Product Development, 229-245).
  • the sterility and microbiological integrity of the composition must be ensured during the whole period of use, irrespective of any possible challenging situation arisen during use, typically, the contact of the tip of the dispenser with contaminated surfaces. From a regulatory point of view, furthermore, the evidence of the required sterility in such “in use” conditions must be conclusive. That is why, in general, the PFMD systems available so far in the market for anti-glaucoma medications and, in particular, for prostaglandin analogues, are not recommended to be used for long treatment periods, namely, of more than one month, after Its first opening, even If they comprise such anti-contamination closure systems,
  • the object of the present invention is a preservative-free ophthalmic composition
  • a preservative-free ophthalmic composition comprising ,a : prostaglandin analogue for use in the reduction of elevated intraocular pressure during a treatment period of at least 90 days
  • toother aspect of the invention is a method for preparing a medicament suitable for the treatment of elevated intraocular pressure during a treatment period of at least 90 days:.
  • the object of the: present invention is a preservative-free ophthalmic composition
  • the ophthalmic composition is an aqueous solution having a viscosity comprised between 1 and 5 mPa-s, measured in a rotary viscometer at 20°C at a shear rate of “100-200" s-1: and
  • the ophthalmic composition is in a multi-dose dispensing device, which comprises a container where the ophthalmic composition is housed and a nozzle, said nozzle comprising means for preventing microbial contamination; characterized in that the total amount of composition necessary for said treatment period is contained In a single multi-dose dispensing device and the composition remains microbiologically acceptable during use for a period of time after the first opening of the container that is equivalent to said treatment period, as assessable in a microbiological test comprising repeated microbial challenge with four microorganisms, wherein said four microorganisms consist of one gram-negative bacterium, one gram-positive bacterium, one fungus of the Aspergillus genus and Candida albicans.
  • the authors of the present invention have developed a prostaglandin preservative-free ophthalmic composition in a multi-dose dispensing device, for the treatment of elevated intraocular pressure during a period of at least 90 days using a single formulation unit, as the ophthalmic composition remains microbiologically acceptable while in use during said period, as assessed in a very demanding microbiological test which simulates the real-life usage conditions of the product by patients, including any possible misuse or inappropriate storage of the product.
  • the concentration of a component in the ophthalmic composition expressed as % (w/v) means grams of said component per 100 ml of composition.
  • the microbiological test used to assess the microbiological acceptability of the composition comprises repeated microbial challenge with four microorganisms, wherein said four microorganisms consist of one gram-negative bacterium, one gram-positive bacterium, one fungus of the Aspergillus genus and Candida albicans.
  • the gram-negative bacterium is Pseudomonas aeruginosa.
  • the gram-positive bacterium is Staphylococcus aureus.
  • the fungus of the Aspergillus genus is Aspergillus brasiliensis.
  • the four microorganisms used in the microbiological test are Pseudomonas aeruginosa, Staphylococcus aureus, Aspergillus brasiliensis and Candida albicans.
  • the microbial challenge means that the tip of the nozzle is dipped in a contaminated challenge suspension comprising the stated microorganisms, preferably, using separated suspensions each containing one of said microorganisms.
  • a contaminated challenge suspension comprising the stated microorganisms, preferably, using separated suspensions each containing one of said microorganisms.
  • the cap of the nozzle of each challenged sample is removed, the tip of the nozzle is immersed into the tested contaminated solution during about 5 seconds, then the system is removed from the contaminated suspension, and the cap is again placed on the nozzle.
  • the sample can be stored at room temperature, without wiping the tip, until the next actuation.
  • Said contaminated suspensions used for the microbiological challenge preferably contain at least 10 6 colony forming units (CFUs) of each germ, typically about 10 6 CFUs.
  • test period is equivalent to the intended treatment period with a single multi-dose unit.
  • Equivalent in this context means at least the same period of time, typically about the same period of time.
  • the test period is therefore of at least 90 days, for example, between 90 and 100 days, preferably between 90 and 95 days.
  • the challenge with the microbial suspensions is repeated preferably at least 4 times, for example, 4, 5, 6, 7 or 8 times, preferably at least 5 times, and more preferably 6 times.
  • Said challenges with the microorganisms preferably are evenly distributed along the testing period.
  • the first challenge is performed the first day of the test
  • the last challenge is performed between 10-20 days before the end of the test, for example about 14 days before the end of the test and the rest of challenges are allocated in between.
  • the time period between each challenge ranges from 13 to 20 days.
  • one drop of the composition is normally dispensed every day.
  • the cap is removed from the nozzle, the dispenser is normally actuated once, tip downward, to deliver one drop of the composition and the tap is again replaced.
  • the samples are stored at room temperature, without wiping the tip, until next actuation.
  • dispensing one drop “every day” it suffices to dispense one-drop, once daily, at least 5 days a week.
  • dispensing one-drop, once daily, 5 days a week may be more convenient as no drop dispensing at the weekend is required.
  • the preservative-free ophthalmic composition of the present invention remains microbiologically acceptable during the test period.
  • “Microbiologically acceptable”, as used herein, means that the drops delivered and the composition inside the bottle fulfil certain acceptance criteria during all the test period, namely, low microbial bioburden of the delivered drops and no contamination (sterility) of the bottle content.
  • a sterility assay for each strain tested is performed at different time points during the test, according to European Pharmacopoeia 2.6.1.
  • four samples are used for each testing, at each time point and the sterility of the composition inside the container is checked.
  • the composition inside the container is sampled using a syringe and is put onto a filter of 0.45 ⁇ m, then the filter is transferred to a culture medium, which typically is TSB or TRB, and the inoculum is incubated for about 14 days at 30-35°C (for TSB) or 20-25°C (for TRB). Then it is observed whether any microbial growth is detected. Sterility means absence of any microbial growth.
  • the sterility is assessed at least 2 times during the test period, preferably at least 3 times, more preferably at least 4 times, and more preferably 4 times.
  • the last sterility assay is performed about the last day of the test, while the other sterility checks may be performed at any time during the test period, distributed along said period, for example, the sterility assay may be performed 2-5 days after a challenge with the microorganisms, as disclosed above.
  • Bioburden testing for each microorganism is repeated several times during the testing period. Bioburden test is repeated at least 2 times, preferably at least 3 times and more preferably at least 4 times during the testing period. For fungi, each repetition of the bioburden testing is typically performed at one point after a challenge with the microorganism (i.e., contamination of the tip of the device, as disclosed above), typically about 14 days after the challenge. For bacteria, each repetition of the bioburden testing is typically performed at three time points after a challenge with the microorganism, typically, 24h, 3 days and 14 days after the microbial challenge. An initial bioburden control test is also performed at the beginning of the test period (TO) for every microorganism.
  • TO test period
  • At least one sample per microorganism is tested, typically about 2-5 samples per microorganism.
  • the samples are contaminated as described above, i.e., the tip of the nozzle is dipped in a contaminated challenge suspension comprising the microorganism.
  • the bioburden level is calculated (“initial bioburden level”).
  • the bioburden test is performed according to well-known methods, for example as disclosed in Eur. Ph. Typically, 2 drops of the composition tested are delivered in a culture medium, the plates are incubated for 5 days at temperature 30-35°C, and then the number of colonies is counted to determine the colony forming units (CPUs).
  • CPUs colony forming units
  • the “low microbial burden” requirement is defined as follows:
  • the highly demanding microbiological test as above described allows to guarantee the microbiological acceptability of the ophthalmic composition contained in a multi-dose dispensing device unit while in use during the intended treatment period, taking into account any possible misuse or inappropriate storage of the product.
  • This guarantee in particular, is essential for the acceptability of the intended use by the relevant medicinal regulatory authorities.
  • multi-dose dispensing device is understood as the whole primary package containing the preservative-free ophthalmic composition and typically comprises a container where the composition is housed, a nozzle which allows for the dropwise delivery of the composition, and a cap covering the nozzle.
  • the container of said dispensing device may be also indistinctly referred to herein as bottle, reservoir, or vessel.
  • Said container is made of a flexible pharmaceutically acceptable packaging material, as are well-known in the art, for example, a polymer selected from the group consisting of polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET), polyvinyl chloride, acrylic resins, polystyrene, polymethylmethacrylate, nylon 6 and mixtures thereof.
  • the container is made of polypropylene (PP) or polyethylene (PE), preferably, low-density polyethylene (LDPE). These materials are widely commercially available from companies such as Dow or LyondellBasell.
  • One preferred material for the container is low-density polyethylene (LDPE) Purell PE 1840H (LyondellBasell).
  • the containers are manufactured according to well-known techniques, typically by injection blow moulding.
  • the volume of the container is suitably adapted to house the required volume of the ophthalmic composition.
  • the amount of the composition is calculated for the required treatment period of at least 90 days, typically 90-100 days, or 90-95 days, i.e., which corresponds to about 3 months.
  • the volume of the composition for such duration ranges from about 7 ml to about 15 ml, depending on the particular active ingredient and the particular formulation.
  • the nozzle of the multi-dose dispensing device allows for the dropwise delivery of the formulation and comprises means for preventing microbial contamination of said composition.
  • the prevention of the microbial contamination relates both during the shelflife, i.e., during storage before being used, and, particularly, also during use after the first opening of the dispensing device.
  • the prevention of microbial contamination during shelf-life is conventionally performed by shielding the contents of the container from the environment, as is standard practice in the art, typically, by airtight assembling of the container, the nozzle and the cap; the cap typically tightly engages the nozzle and protects the nozzle tip.
  • the cap may optionally include a collar that is broken and removed after the first opening the dispenser and acts as a guarantee tamper-evident seal, to ensure that the device has not been opened before the first use.
  • the nozzle comprises means for preventing the microbial contamination also after the first opening of the dispensing device, while the composition is in use.
  • the risk of contamination increases due to possible misuse, including contacting the tip of the nozzle with contaminated surfaces, for example, by direct contact with the eye surface, or due to incorrect closure of the device after use.
  • Such means for preventing the microbial contamination during use consist in a closure system fitted in the nozzle of the device, which acts as a barrier, avoiding the entry of pathogens inside the device.
  • PFMD preservative-free multidose devices
  • PFMD preservative-free multidose devices
  • They are typically based either on a pump system or on a non-return valve combined with a filter for the compensating air entering into the container, for example as disclosed in Yoon et al., Packaging Development: Multi-dose container closure for preservative free products, extractable/leachables from packaging, new technologies, in: Neervannan, S., Kompella, U.B. (eds) Ophthalmic Product Development. AAPS Advances in the Pharmaceutical Sciences Series, vol 37. Springer, Ophthalmic Product Development, 229-245.
  • Suitable examples of commercially available closure systems for PFMD delivery devices based on a pump are COMOD® (Ursapharm) and 3K® (Adelphi Healthcare Packaging).
  • COMOD® Ursapharm
  • 3K® Addelphi Healthcare Packaging
  • the pump typically, when the pump is activated, the product contained in the dosing chamber of the pump is subjected to pressure, which opens the outlet valve and releases a drop. Upon completion of the dosing process, the valve closes immediately afterwards and therefore backflow of the product is prevented.
  • the pump is reset to its initial position and a further aliquot of the product is drawn from the container into the dosing chamber.
  • 3K® system there is airtight sachet inside the container, where the composition is packaged, which at no point comes into contact with the surrounding air.
  • Novelia® the intake of air to re-equilibrate the pressure into the bottle takes place via a venting system comprising a silicone membrane, in the form of a silicone plug, to filter the returning air, which is separated from the non-return valve.
  • a venting system comprising a silicone membrane, in the form of a silicone plug, to filter the returning air, which is separated from the non-return valve.
  • the intermolecular distance in this silicone membrane is of the order of nanometers, allowing the passage of air, but preventing the passage of any liquid or solid, including bacteria.
  • the anti-microbial effectiveness may be enhanced by the use of a silver releasing agent embedded into the top of the nozzle that is able to release silver ions, a well-known antibacterial agent.
  • a silver releasing agent embedded into the top of the nozzle that is able to release silver ions
  • Bactiglas® is a commercially available material, which is able to release silver ions in a controlled and sustained way.
  • This silver releasing agent may be embedded in the tip of the nozzle or on the part of the cap in contact with said tip or, preferably, in both. In this way, the possible residual drop of the product which remains in the tip of the dispenser stays in contact with such silver anti-microbial agent.
  • the nozzle is made of different materials.
  • the structural components are typically made of high-density polypropylene (HOPE), while other parts may be made of different materials.
  • HOPE high-density polypropylene
  • the valve and the plug for filtering the air are made of silicone.
  • the cap covers the nozzle of the device, and is typically a screw cap made of HOPE.
  • the internal part of the top of the cap, which is in contact with the orifice of the nozzle, as disclosed above, can contain a silver releasing agent.
  • the preservative-free ophthalmic composition for the use according to the present invention comprises a prostaglandin analogue.
  • Prostaglandin analogues are specifically prostaglandin F2a (PGF2a) analogues, which, as is well known in the art, are a class of drugs that can bind to prostaglandin receptors FP or EP.
  • Prostaglandin analogues topically administered to the eye, are first-choice therapy for treating glaucoma, due to their high clinical efficacy to reduce intraocular pressure (IOP) by once-daily dosage regimens.
  • IOP intraocular pressure
  • the prostaglandin analogue of the present invention is selected from bimatoprost, latanoprost, travoprost, and tafluprost.
  • Latanoprost and travoprost are ester prodrug analogues, while bimatoprost is an amide prodrug.
  • Tafluprost is also an ester prodrug, wherein the C-15 hydrogen and hydroxyl group are substituted with two fluorine atoms.
  • the prostaglandin analogue is selected from bimatoprost, latanoprost and travoprost.
  • the prostaglandin analogue is selected from bimatoprost and latanoprost.
  • the prostaglandin composition for the therapeutic use according to the present invention is a “preservative-free” ophthalmic composition.
  • preservative-free means that the ophthalmic composition of the present invention does not comprise any preservative conventionally used for the preservation of ophthalmic compositions, for example, the composition does not contain quaternary ammonium compounds, such as benzalkonium chloride (BAK).
  • quaternary ammonium compounds such as benzalkonium chloride (BAK).
  • Other pharmaceutically acceptable preservatives for ophthalmic solutions, which are also excluded from the present composition are, for example, parabens (such as ethylparaben or butylparaben), chlorhexidine, benzethonium chloride, or sorbic acid or salts (such as potassium sorbate), among others.
  • the ophthalmic composition of the invention comprises the prostaglandin analogue, as disclosed above.
  • the amount of the prostaglandin analogue in the ophthalmic composition ranges from 0.001% to 0.5% (w/v), more preferably from 0.002% to 0.3% (w/v).
  • the ophthalmic composition may contain a second anti-glaucoma active ingredient, as a fixed-dose combination.
  • the ophthalmic composition may optionally also contain a betablocker.
  • Beta-blockers suitable to be used in combination with the prostaglandin analogue are, for example, timolol, levobunolol, metipranolol, carteolol or betaxolol, or a pharmaceutically acceptable salt thereof.
  • One preferred beta-blocker is timolol, or an acceptable salt thereof.
  • One preferred salt of timolol is timolol maleate.
  • the ophthalmic composition comprises timolol, or a pharmaceutically acceptable salt thereof, as additional active ingredient, it is generally in an amount comprised between 0.1% (w/v) and 1.0% (w/v), preferably comprised between 0.2% (w/v) and 0.8% (w/v), more preferably comprised between 0.3% (w/v) and 0.7% (w/v), still more preferably comprised between 0.4% (w/v) and 0.6% (w/v), and still more preferably about 0.5% (w/v), expressed as amount of timolol.
  • the ophthalmic composition is an aqueous solution and is characterized in that it has a viscosity comprised between 1 and 5 mPa-s.
  • the viscosity of the ophthalmic composition may be measured according to standard procedures, typically, using a viscometer (or viscosimeter), as are well-known in the art.
  • a rotary viscometer may be used, in particular, a concentric cylinder viscometer, comprising two coaxial cylinders.
  • a Brookfield viscometer is the Brookfield viscometer.
  • the viscosity value of the ophthalmic composition is measured at about 20°C, using a rotary viscometer, for example, a concentric cylinder viscometer, in particular, a Brookfield type viscometer, at a shear rate of from 100 to 200 s -1 , preferably at a shear rate of about 100 s -1 , and preferably using UL Adapter.
  • a Brookfield type viscometer at 20 ° C, at a shear rate of 100 s -1 , and preferably using UL Adapter.
  • the viscosity is comprised between 1 and 4 mPa-s., preferably comprised between 1 and 3 mPa-s, and more preferably comprised between 1 and 2 mPa-s.
  • the ophthalmic composition of the present invention is aqueous, i.e., the solvent is water.
  • the solvent is water.
  • WFI water for injection
  • WFI is generally obtained by water purification using procedures as distillation, deionization, reverse-osmosis, membrane filtration or combination thereof.
  • aqueous ophthalmic composition according to the invention may also comprise conventional pharmaceutically acceptable excipients used in ophthalmic compositions.
  • excipients are well-known in the art and are disclosed, for example, in the book “Handbook of Pharmaceutical Excipients” (8th edition, 2017, Rowe et al., editors, Pharmaceutical Press).
  • ophthalmic composition of the invention are, for example, cosolvents, surfactants, antioxidants, tonicity agents, buffering agents, or mixtures thereof.
  • the aqueous ophthalmic composition may optionally comprise an organic cosolvent.
  • Suitable cosolvents are, for example, propylene glycol or polyethylene glycol, among others. If the composition comprises a cosolvent, it is generally in an amount in the range 0.1 -1 .0% (w/v).
  • the composition may optionally contain a surfactant.
  • surfactants as is well- known in the art, are compounds that lower the surface tension between two liquids or between a liquid and a solid, and they may be non-ionic, anionic or cationic.
  • composition of the invention comprises a surfactant
  • a surfactant it is preferably a non-ionic surfactant, for example, a polyoxyethylene fatty alcohol ether; or a polyoxyethylene fatty acid ester, such as polyoxyethylene sorbitan, mono- or polyester or polyoxyethylene glycerol, mono- or polyester; or a fatty acid ester, such as a sorbitan fatty acid ester, or a glycerol fatty acid ester; or poloxamers, among others, or mixtures thereof.
  • a non-ionic surfactant for example, a polyoxyethylene fatty alcohol ether; or a polyoxyethylene fatty acid ester, such as polyoxyethylene sorbitan, mono- or polyester or polyoxyethylene glycerol, mono- or polyester; or a fatty acid ester, such as a sorbitan fatty acid ester, or a glycerol fatty acid ester; or poloxamers, among others, or mixtures thereof.
  • the non-ionic surfactant is selected from the group consisting of polysorbate 80, polysorbate 60, polysorbate 40, polysorbate 20, polysorbate 65, polyoxyethylene sorbitan trioleate, polyoxyethylene (10) hydrogenated castor oil, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (50) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil, polyoxyethylene (40) stearate, and mixtures thereof; and more preferably is selected from polysorbate 80 and polyoxyethylene (40) hydrogenated castor oil.
  • the ophthalmic composition comprises a surfactant
  • it is generally in an amount comprised between 0.01% (w/v) and 1 .0% (w/v), preferably comprised between 0.01% (w/v) and 0.75% (w/v), and more preferably comprised between 0.04% (w/v) and 0.60% (w/v).
  • the composition may optionally contain an antioxidant.
  • Antioxidants are substances that prevent the oxidation of other molecules.
  • ethylenediamine tetraacetic acid also known as edetic acid
  • salts thereof for example, disodium edetate
  • the composition comprises an antioxidant, it is generally in an amount comprised in the range 0.005-0.1% (w/v), preferably in the range 0.01 -0.05% (w/v).
  • the ophthalmic composition of the invention may optionally comprise a tonicity agent.
  • Tonicity agents are substances added to produce solutions which are approximately isotonic relative normal tears, in order to reduce pain and tissue irritation on application of the composition.
  • Suitable osmolality values for the ophthalmic composition are comprised between 250 and 320 mOsm/kg.
  • Suitable tonicity agents added to adjust the osmolality of the solution are, for example, sodium chloride, potassium chloride, calcium chloride, propylene glycol, glycerol, sorbitol or mannitol.
  • the tonicity agent is selected from sodium chloride, mannitol and glycerol.
  • the osmolality can be measured using known methods, typically using an osmometer.
  • the ophthalmic composition of the invention may also contain a buffering agent.
  • a buffering agent is a substance or substance combination, generally consisting of an acid and its conjugate base, capable in solution of neutralizing both acids and bases and thereby maintaining stable the pH of the solution.
  • the preparation of buffering agents is well known.
  • the phosphate buffer is typically prepared as a mixture of the dihydrogen phosphate ion and the hydrogen phosphate ion, for example using the sodium dihydrogen phosphate salt (NaH 2 PO 4 , or monosodium phosphate) and the sodium hydrogen phosphate salt (Na 2 HPO 4 , or disodium phosphate).
  • the acetate buffer can be prepared with acetic acid and sodium acetate; the citrate buffer can be prepared with citric acid and sodium citrate; or the borate buffer can be prepared with boric acid and disodium tetraborate, for example.
  • Mixed buffers are also suitable, for example the citrate-phosphate buffer, prepared with citric acid and disodium hydrogen phosphate.
  • the composition of the invention comprises a buffering agent selected from phosphate buffer, borate buffer, citrate buffer and citrate-phosphate buffer.
  • the pH of the ophthalmic solution is adjusted to a value ranging from about 4.5 to about 7.5.
  • an acid and/or base are added to the composition, typically, hydrochloric acid and/or sodium hydroxide.
  • the pH of the composition is measured using known procedures, typically, using a pH-meter.
  • the ophthalmic composition of the invention is prepared according to conventional methods, typically, by dissolving the prostaglandin analogue, optionally an additional active ingredient, and any optional excipients in water, adjusting the pH value if needed, and sterilizing, either by aseptic filtration through a 0.22- ⁇ m filter or by autoclaving.
  • the total amount of the ophthalmic composition necessary for the treatment period of at least 90 days is contained in a single multi-dose dispensing device. Accordingly, the suitable volume of the composition is calculated, which is sufficient for said treatment period, considering the concentration of the prostaglandin analogue in the composition and the recommended therapeutic dose, as is well-known for the skilled in the art.
  • a suitable container is selected for the required volume of the composition, and the composition is filled therein.
  • the corresponding nozzle is assembled, typically screwed, with a cap covering the nozzle.
  • the preservative-free ophthalmic composition is an aqueous solution comprising latanoprost as active ingredient, optionally in combination with timolol, or a pharmaceutically acceptable salt thereof, the non-ionic surfactant polysorbate 80, disodium edetate as antioxidant, a tonicity agent, and a buffering agent.
  • said preservative-free ophthalmic composition is an aqueous solution comprising:
  • - latanoprost in a concentration comprised in the range 0.001 -0.010% (w/v), preferably in the range 0.002-0.008% (w/v), more preferably in the range 0.003- 0.007% (w/v), still more preferably in the range 0.004-0.006% (w/v), still more preferably in a concentration of about 0.005% (w/v), and still more preferably in a concentration of 0.005% (w/v);
  • timolol or a pharmaceutically acceptable salt thereof, preferably timolol maleate, in a concentration comprised in the range 0.1-1.0% (w/v), preferably in the range 0.2-0.8% (w/v), more preferably in the range 0.3-0.7% (w/v), still more preferably in the range 0.4-0.6% (w/v), still more preferably in a concentration of about 0.5% (w/v), and still more preferably in a concentration of 0.5% (w/v), expressed as the concentration of timolol;
  • - polysorbate 80 in a concentration comprised in the range 0.01 -1 .0% (w/v), preferably in the range 0.01 -0.50% (w/v), more preferably in the range 0.02-0.10% (w/v), still more preferably in the range 0.03-0.07% (w/v), still more preferably in the range 0.04- 0.06% (w/v), and still more preferably is about 0.05% (w/v);
  • - disodium edetate in a concentration comprised in the range 0.01 -0.05% (w/v), preferably in the range 0.01 -0.04% (w/v), more preferably is about 0.02% (w/v);
  • the tonicity agent in an amount sufficient to adjust the osmolality to a value comprised in the range 250-320 mOsmol/kg, preferably wherein the tonicity agent is selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, propylene glycol, glycerol, sorbitol, mannitol and mixtures thereof, and more preferably the tonicity agent is sodium chloride; and
  • an ophthalmically-acceptable buffering agent preferably selected from phosphate buffer, borate buffer, citrate buffer and citrate-phosphate buffer, more preferably is a phosphate buffer;
  • a pH adjusting agent such as hydrochloric acid and/or sodium hydroxide to adjust the pH of the solution to a value in the range 5.5-6.5, preferably in the range 5.S-6.2; and
  • the preservative-free ophthalmic composition is an aqueous solution which essentially consists of latanoprost, optionally timolol, or a pharmaceutically acceptable salt thereof, polysorbate 80, sodium edetate, a tonicity agent, a buffering system, optionally a pH adjusting agent, and water as solvent, according to the preferences disclosed above.
  • the preservative-free ophthalmic composition is an aqueous solution comprising bimatoprost as active ingredient, optionally in combination with timolol, or a pharmaceutically acceptable salt thereof, a tonicity agent, and a buffering agent.
  • said preservative-free ophthalmic composition is an aqueous solution comprising:
  • the tonicity agent in an amount sufficient to adjust the osmolality to a value comprised in the range 250-320 mOsmol/kg, preferably wherein the tonicity agent is selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, propylene glycol, glycerol, sorbitol, mannitol and mixtures thereof, and more preferably the tonicity agent is sodium chloride; and
  • an ophthalmically-acceptable buffering agent preferably selected from phosphate buffer, borate buffer, citrate buffer and citrate-phosphate buffer, more preferably is citrate-phosphate buffer;
  • a pH adjusting agent such as hydrochloric acid and/or sodium hydroxide to adjust the pH of the solution to a value in the range 6.S-7.6;
  • the preservative-free ophthalmic composition is an aqueous solution which essentially consists of bimatoprost, optionally timolol, or a pharmaceutically acceptable salt thereof, a tonicity agent, a buffering system, optionally a pH adjusting agent, and water as solvent, according to the preferences disclosed above.
  • the preservative-free ophthalmic composition is an aqueous solution comprising travoprost as active ingredient, optionally in combination with timolol, or a pharmaceutically acceptable salt thereof, the non-ionic surfactant polyoxyethylene (40) hydrogenated castor oil, propylene glycol as cosolvent, a tonicity agent, and a buffering agent.
  • said preservative-free ophthalmic composition is an aqueous solution comprising:
  • - travoprost in a concentration comprised in the range 0.001 -0.010% (w/v), preferably in the range 0.002-0.007% (w/v), more preferably in the range 0.003-0.005% (w/v), still more preferably in a concentration of about 0.004% (w/v), and still more preferably in a concentration of 0.004% (w/v);
  • timolol or a pharmaceutically acceptable salt thereof, preferably timolol maleate, in a concentration comprised in the range 0.1-1.0% (w/v), preferably in the range 0.2-0.8% (w/v), more preferably in the range 0.3-0.7% (w/v), still more preferably in the range 0.4-0.6% (w/v), still more preferably in a concentration of about 0.5% (w/v), and still more preferably in a concentration of 0.5% (w/v), expressed as the concentration of timolol;
  • a cosolvent which is preferably propylene glycol, in a concentration comprised in the range 0.1 -1.0% (w/v), preferably in the range 0.3-0.8% (w/v);
  • the tonicity agent in an amount sufficient to adjust the osmolality to a value comprised in the range 250-320 mOsmol/kg, preferably wherein the tonicity agent is selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, propylene glycol, glycerol, sorbitol, mannitol and mixtures thereof, and more preferably the tonicity agent is a mixture of sodium chloride and mannitol; and
  • an ophthalmically-acceptable buffering agent preferably selected from phosphate buffer, borate buffer, citrate buffer and citrate-phosphate buffer, more preferably is borate buffer;
  • a pH adjusting agent such as hydrochloric acid and/or sodium hydroxide to adjust the pH of the solution to a value in the range 4.6-6.8;
  • the preservative-free ophthalmic composition is an aqueous solution which essentially consists of travoprost, optionally timolol, or a pharmaceutically acceptable salt thereof, propylene glycol, polyoxyethylene (40) hydrogenated castor oil, a tonicity agent, a buffering system, optionally a pH adjusting agent, and water as solvent, according to the preferences disclosed above.
  • the preservative-free ophthalmic composition is an aqueous solution comprising tafluprost as active ingredient, optionally in combination with timolol, or a pharmaceutically acceptable salt thereof, the non-ionic surfactant polysorbate 80, disodium edetate as antioxidant, a tonicity agent, and a buffering agent.
  • said preservative-free ophthalmic composition is an aqueous solution comprising:
  • - polysorbate 80 in a concentration comprised in the range 0.01 -1 .0% (w/v), preferably in the range 0.03-0.50% (w/v), more preferably in the range 0.05-0.15% (w/v), still more preferably in the range 0.07-0.08% (w/v), and still more preferably is about 0.075% (w/v);
  • - disodium edetate in a concentration comprised in the range 0.01 -0.10% (w/v), preferably in the range 0.02-0.07% (w/v), more preferably is about 0.05% (w/v);
  • the tonicity agent in an amount sufficient to adjust the osmolality to a value comprised in the range 250-320 mOsmol/kg, preferably wherein the tonicity agent is selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, propylene glycol, glycerol, sorbitol, mannitol and mixtures thereof, and more preferably the tonicity agent is glycerol; and
  • an ophthalmically-acceptable buffering agent preferably selected from phosphate buffer, borate buffer, citrate buffer and citrate-phosphate buffer, more preferably is a phosphate buffer;
  • a pH adjusting agent such as hydrochloric acid and/or sodium hydroxide to adjust the pH of the solution to a value in the range 5.5-6.5, preferably in the range 5.8-6.2;
  • the preservative-free ophthalmic composition is an aqueous solution which essentially consists of tafluprost, optionally timolol, or a pharmaceutically acceptable salt thereof, polysorbate 80, sodium edetate, a tonicity agent, a buffering system, optionally a pH adjusting agent, and water as solvent, according to the preferences disclosed above.
  • the preservative-free ophthalmic composition according to the present invention is for use in the reduction of elevated intraocular pressure.
  • the reduction of elevated intraocular pressure is also referred to herein as the treatment of elevated intraocular pressure, and both terms can be used interchangeably.
  • the therapeutic use according to the present invention relates to the treatment of a human subject, i.e. a patient in need thereof.
  • the preservative-free ophthalmic composition according to the present invention is preferably for use in the reduction of intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.
  • the present invention relates to said therapeutic use of the preservative-free ophthalmic composition during a treatment period of at least 90 days using a single ophthalmic composition in a single multi-dose dispensing device, and administered during the treatment period according to a suitable dosage schedule.
  • the treatment period is of at least 90 days.
  • the treatment period ranges from 90 to 100 days, preferably from 90 to 95 days.
  • Another aspect of the present invention relates to a method for preparing an ophthalmic medicament suitable for the treatment of elevated intraocular pressure during a treatment period of at least 90 days comprising the following -steps: a) preparing a preservative-free ophthalmic aqueous solution comprising a prostaglandin analogue selected from bimatoprost, latanoprost, travoprost, and tafluprost, having a viscosity comprised between 1 and 5 mPa-s, measured in a rotary viscometer at 20°C at a shear rate of “100-200” s-1; b) packing the necessary amount of the ophthalmic composition of step a) for said treatment period in a multi-dose dispensing device, which comprises a container where the ophthalmic oomposition is housed: and a nozzle, said nozzle comprising means for preventing microbial contamination; and c) testing Whether the composition remains microbiologically acceptable during use for
  • this method includes all the definitions and preferences as disclosed above for the microbiological test, the multi-dose dispensing device, the prostaglandin analogue, the ophthalmic composition and the duration of the treatment period.
  • the method typically, involves the preparation of a batch of said ophthalmic medicament, and testing the microbiological acceptability in a representative number of units, it is understood that the batch will be considered acceptable Only if the testing of step c) is positive, Le., if the composition remains microbiologically acceptable in said test.
  • composition comprising a prostaglandin analogue selected from bimatoprost, latanoprost, travoprost, and tafluprost for use in the reduction of elevated intraocular pressure during a treatment period of at least 90 days, wherein:
  • the ophthalmic composition is an aqueous solution having a viscosity comprised between 1 and 5 mPa-s, measured in a rotary viscometer at 20°C at a shear rate of “100-200” s-1: and
  • the ophthalmic composition is in a multi-dose dispensing device, which comprises a container where the ophthalmic composition is housed and a nozzle, said nozzle comprising means for preventing microbial contamination; characterized in that the total amount of composition necessary for said treatment period is contained in a single multi-dose dispensing device and the composition remains microbiologically acceptable during use for a period of time after the first opening of the container that is equivalent to said treatment periods as assessed in a microbiological test comprising repeated microbial challenge with four microorganisms, wherein said four microorganisms consist of one gram-negative bacterium, one gram-positive bacterium, one fungus of the Aspergillus genus and Candida albicans.
  • CFUs colony forming units
  • ophthalmic composition for use of embodiment 14, wherein the ophthalmic composition comprises a beta-blocker selected from timolol, levobunolol, metipranolol, carteolol or betaxolol, or a pharmaceutically acceptable salt thereof.
  • the beta-blocker is timolol or a pharmaceutically acceptable salt thereof, in an amount comprised between 0.1 % (w/v) and 1.0% (w/v), preferably comprised between 0.2% (w/v) and 0.8% (w/v), more preferably comprised between 0.3% (w/v) and 0.7% (w/v), still more preferably comprised between 0.4% (w/v) and 0.6% (w/v), and still more preferably about 0.5% (w/v).
  • ophthalmic composition for use of embodiment 16, wherein the ophthalmic composition additionally comprises timolol as a second anti-glaucoma agent, preferably in an amount of about 0.5% (w/v).
  • the ophthalmic composition additionally comprises a surfactant, preferably a non-ionic surfactant, more preferably selected from a polyoxyethylene fatty alcohol ether, a polyoxyethylene fatty acid ester, a fatty acid ester, a poloxamer and mixtures thereof, still more preferably selected from the group consisting of polysorbate 80, polysorbate 60, polysorbate 40, polysorbate 20, polysorbate 65, polyoxyethylene sorbitan trioleate, polyoxyethylene (10) hydrogenated castor oil, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (50) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil, polyoxyethylene (40) stearate, and mixtures thereof, and still more preferably is selected from polysorbate 80 and polyoxyethylene (40) hydrogenated castor oil.
  • a surfactant preferably a non-ionic surfactant, more preferably selected from a polyoxyethylene fatty alcohol ether, a polyoxyethylene fatty acid ester, a
  • ophthalmic composition for use according to any one of embodiments 1 to 21 , wherein the ophthalmic composition additionally comprise an antioxidant, preferably edetic acid or a salt thereof, preferably in an amount comprised in the range 0.005-0.1% (w/v), more preferably in the range 0.01 -0.05% (w/v).
  • an antioxidant preferably edetic acid or a salt thereof, preferably in an amount comprised in the range 0.005-0.1% (w/v), more preferably in the range 0.01 -0.05% (w/v).
  • composition for use according to any one of embodiments 1 to 22, wherein the composition comprises a tonicity agent to adjust the osmolality of the composition to a value comprised between 250 and 320 mOsm/kg.
  • the tonicity agent is selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, propylene glycol, glycerol, sorbitol, mannitol and mixtures thereof, preferably is selected from sodium chloride, mannitol, glycerol, and mixtures thereof.
  • composition for use according to any one of embodiments 1 to 24, wherein the composition comprises a buffering agent, preferably selected from phosphate buffer, borate buffer, citrate buffer and citrate-phosphate buffer and optionally hydrochloric acid and/or sodium hydroxide to adjust the pH of the composition to a value in the range 4.5-7.5.
  • a buffering agent preferably selected from phosphate buffer, borate buffer, citrate buffer and citrate-phosphate buffer and optionally hydrochloric acid and/or sodium hydroxide to adjust the pH of the composition to a value in the range 4.5-7.5.
  • 26. The preservative-free ophthalmic composition for use according to any one of embodiments 1 to 25, wherein it is for the reduction of intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.
  • 27. Method for preparing an ophthalmic medicament suitable for the treatment of elevated intraocular pressure during a treatment period of at least 90 days comprising the following steps: a) preparing a preservative-free ophthalmic aqueous solution comprising a prostaglandin analogue selected from btmatopirost. latanoprost.
  • a multi-dose dispensing device which comprises a container where the ophthalmic composition is housed and a nozzle, sard nozzle comprising means for preventing microbial contamination; and c) testing whether the composition remains mtcitibiologioally acceptable during use for a period of time after the first opening of the container that is equivalent to said treatment period, using a microbiological test comprising repeated microbial challenge with four microorganisms, wherein said four microorganisms consist of one gram-negative bacterium, one gram-positive bacterium, one fungus of the Asperg/7/usgenus and Candida albicans.
  • the viscosity of the composition was 1.27 mPa-s, measured at 20 ° C using a Brookfield viscometer.
  • Example 2 Preparation a multidose ophthalmic composition comprising bimatoprost and timolol suitable for 3 months usage
  • Example 1 The solution prepared in Example 1 was sterilized by filtration through a 0.22 ⁇ m filter. 9 ml of the sterile solution were introduced in a sterile white LDPE bottle (11 ml), having a Novella® nozzle with a tamper-proof HDPE screw cap, comprising a silver agent (Bactiglas®) on the tip of the nozzle and on the inner part of the cap contacting such tip.
  • a sterile white LDPE bottle 11 ml
  • Novella® nozzle with a tamper-proof HDPE screw cap comprising a silver agent (Bactiglas®) on the tip of the nozzle and on the inner part of the cap contacting such tip.
  • the multidose dispensing device comprising the bimatoprost/timolol composition was subjected to a microbiological test to assess microbiological compliance during use for a period of 91 days.
  • the microbial challenge was performed using the following microorganisms:
  • Samples 1 -80 were used for bioburden and sterility testing along the 91 -day testing period.
  • Samples 81 -98 were used for checking initial (TO) bioburden and sterility.
  • the samples were contaminated with the stated microorganisms, and immediately after contamination, the bioburden level was calculated.
  • the cap of the nozzle of each bottle was removed, one drop was delivered, and the cap was screwed again. Between each dispensation, the samples were stored at the room temperature in upright position without wiping the tip.
  • a repeated contamination of the samples was performed at the start (D1 ) of the in-use testing and every two weeks during 90 days.
  • contamination of the samples was performed on days D1 , D15, D29, D43, D57 and D77, according to the above table.
  • the contamination of the samples was performed according to the following procedure: the cap of the nozzle of each bottle was removed, the tip of the nozzle was immersed into the contaminated solution during about 5 seconds, the tip was then removed from the contaminated solution, and the cap was screwed again. Between each dispensation, the samples were stored at the room temperature in upright position without wiping the tip.
  • Bioburden tests for fungi were performed on days D29, D43, D72 and D91 , corresponding to 14 days after contamination.
  • Bioburden tests for bacteria were performed on days D16, D30, D58 and D78, corresponding to 24h after contamination, on days D18, D32, D60 and D80, corresponding to 3 days after contamination, and also on days D29, D43, D72 and D91 , corresponding to 14 days after contamination.
  • two drops of the composition from each tested sample are delivered in a culture medium comprising tryptone salt and the number of colonies is counted to determine the number of CFUs.
  • the content of the analysed systems was sampled with a syringe after cleaning the area of drilling with alcohol.
  • the content was put onto a filter 0.45 ⁇ m, and the filter was transferred to TSB or TRB culture medium.
  • the cultures were incubated for 14 days at 30-35°C (TRB) and 25-25°C (TSB).
  • the acceptance criteria for sterility tests was absence of any growth, i.e., that the content of the device remains sterile.
  • bioburden tests for the dispensed drops the number of colonies for each microorganism was counted to determine the colony forming units, and the log reduction was calculated at each time point.
  • the viscosity of the composition was 1.06 mPa-s (measured at 20°C using a Brookfield viscometer).
  • Example 4 Preparation a multidose ophthalmic composition comprising bimatoprost suitable for 3 months usage
  • Example 3 The solution prepared in Example 3 was sterilized by filtration through a 0.22 ⁇ m filter. 9 ml of the sterile solution were introduced in a sterile white LDPE bottle (1 1 ml), having a Novelia® nozzle with a tamper-proof HDPE screw cap, comprising a silver agent (Bactiglas®) on the tip of the nozzle and on the inner part of the cap contacting such tip.
  • a sterile white LDPE bottle (1 1 ml)
  • a Novelia® nozzle with a tamper-proof HDPE screw cap comprising a silver agent (Bactiglas®) on the tip of the nozzle and on the inner part of the cap contacting such tip.
  • the multidose dispensing device comprising the bimatoprost composition was subjected to a microbiological test to assess microbiological compliance during use for a period of 91 days, following an analogous procedure as disclosed in Example 2.
  • the viscosity of the composition was 1 .2 mPa s.
  • Example 6 Preparation a multidose ophthalmic composition comprising latanoprost suitable for 3 months usage
  • Example 5 The solution prepared in Example 5 was sterilized by filtration through a 0.22 ⁇ m filter. 7.5 ml of the sterile solution were introduced in a sterile white LDPE bottle (10 ml), having a 3K® nozzle with a tamper-proof HDPE screw cap, comprising a silver coil in the 3K pump tip which protects against microbial contamination.
  • the multidose dispensing device comprising the latanoprost composition was subjected to a microbiological test to assess microbiological compliance during use for a period of 91 days, following an analogous procedure as disclosed in Example 2. It was confirmed that the microbial acceptance criteria, both for sterility and bioburden, were fulfilled for all time points checked along the test duration.
  • the viscosity of the composition was 1.2 mPa s (measured at 20°C using a Brookfield viscometer).
  • Example 8 Preparation a multidose ophthalmic composition comprising latanoprost and timolol suitable for 3 months usage
  • Example 7 The solution prepared in Example 7 was sterilized by filtration through a 0.22 ⁇ m filter. 7.5 ml of the sterile solution were introduced in a sterile white LDPE bottle (10 ml), having a 3K® nozzle with a tamper-proof HDPE screw cap, comprising a silver coil in the 3K pump tip, which protects against microbial contamination.
  • the multidose dispensing device comprising the latanoprost-timolol composition was subjected to a microbiological test to assess microbiological compliance during use for a period of 91 days, following an analogous procedure as disclosed in Example 2. It was confirmed that the microbial acceptance criteria, both for sterility and bioburden, were fulfilled for all time points checked along the test duration.
  • the viscosity of the composition was 1.5 mPa s ((measured at 20°C using a Brookfield viscometer).
  • Example 10 Preparation a multidose ophthalmic composition comprising travoprost suitable for 3 months usage
  • Example 9 The solution prepared in Example 9 was sterilized by filtration through a 0.22 ⁇ m filter. 7.5 ml of the sterile solution were introduced in a sterile white LDPE bottle (10 ml), having a 3K® nozzle with a tamper-proof HDPE screw cap, comprising a silver coil in the 3K pump tip, which protects against microbial contamination.
  • the multidose dispensing device comprising the travoprost composition was subjected to a microbiological test to assess microbiological compliance during use for a period of 91 days, following an analogous procedure as disclosed in Example 2.
  • the viscosity of the composition was 1 .22 mPa s ((measured at 20°C using a Brookfield viscometer).
  • Example 12 Preparation a multidose ophthalmic composition comprising tafluprost suitable for 3 months usage
  • Example 11 The solution prepared in Example 11 was sterilized by filtration through a 0.22 ⁇ m filter. 9 ml of the sterile solution were introduced in a sterile white LDPE bottle (11 ml), having a Novelia® nozzle with a tamper-proof HDPE screw cap, comprising a silver agent (Bactiglas®) on the tip of the nozzle and on the inner part of the cap contacting such tip.
  • a sterile white LDPE bottle 11 ml
  • Novelia® nozzle with a tamper-proof HDPE screw cap comprising a silver agent (Bactiglas®) on the tip of the nozzle and on the inner part of the cap contacting such tip.
  • the multidose dispensing device comprising the tafluprost composition was subjected to a microbiological test to assess microbiological compliance during use for a period of 91 days, following an analogous procedure as disclosed in Example 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition ophtalmique sans conservateur comprenant un analogue de prostaglandine destiné à être utilisé dans la réduction de la pression intraoculaire élevée pendant une période de traitement d'au moins 90 jours. La composition reste microbiologiquement acceptable pendant l'utilisation pendant ladite période de traitement, telle qu'évaluée dans un test microbiologique comprenant une provocation microbienne répétée avec quatre micro-organismes constitués d'une bactérie à Gram négatif, d'une bactérie à Gram positif, d'un champignon du genre Aspergillus et Candida albicans.
PCT/EP2023/067517 2022-06-27 2023-06-27 Composition ophtalmique sans conservateur comprenant un analogue de prostaglandine WO2024003078A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22460028.8 2022-06-27
EP22460028 2022-06-27

Publications (1)

Publication Number Publication Date
WO2024003078A1 true WO2024003078A1 (fr) 2024-01-04

Family

ID=82656276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/067517 WO2024003078A1 (fr) 2022-06-27 2023-06-27 Composition ophtalmique sans conservateur comprenant un analogue de prostaglandine

Country Status (1)

Country Link
WO (1) WO2024003078A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036847A2 (fr) * 2006-09-21 2008-03-27 Alcon Research, Ltd. Compositions pharmaceutiques aqueuses auto-conservées
WO2012015996A2 (fr) * 2010-07-29 2012-02-02 Allergan, Inc. Solutions de bimatoprost sans conservateur
EP2886130A1 (fr) * 2013-12-23 2015-06-24 Rafarm S.A. Composition pharmaceutique ophtalmique et son procédé de préparation
WO2017066052A1 (fr) * 2015-10-15 2017-04-20 Bridge Pharma, Inc. Formulations et méthodes de traitement de pression intraoculaire élevée
WO2017167457A1 (fr) * 2016-04-01 2017-10-05 Pharmathen S.A. Composition pharmaceutique sans conservateur pour administration ophtalmique, contenant du bimatoprost et du timolol
WO2017182138A1 (fr) * 2016-04-19 2017-10-26 Pharmathen S.A. Compositions ophtalmiques pharmaceutiques sans conservateur
WO2021049963A1 (fr) * 2019-09-13 2021-03-18 Warszawskie Zakłady Farmaceutyczne Polfa Sa Composition pharmaceutique de bimatoprost et de timolol
EP3973954A1 (fr) * 2013-10-15 2022-03-30 Pharmathen S.A. Compositions pharmaceutiques sans conservateur pour l'administration ophtalmique
WO2022096965A1 (fr) * 2020-11-04 2022-05-12 Iromed Group S.r.l. Composition ophtalmique

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036847A2 (fr) * 2006-09-21 2008-03-27 Alcon Research, Ltd. Compositions pharmaceutiques aqueuses auto-conservées
WO2012015996A2 (fr) * 2010-07-29 2012-02-02 Allergan, Inc. Solutions de bimatoprost sans conservateur
EP3973954A1 (fr) * 2013-10-15 2022-03-30 Pharmathen S.A. Compositions pharmaceutiques sans conservateur pour l'administration ophtalmique
EP2886130A1 (fr) * 2013-12-23 2015-06-24 Rafarm S.A. Composition pharmaceutique ophtalmique et son procédé de préparation
WO2017066052A1 (fr) * 2015-10-15 2017-04-20 Bridge Pharma, Inc. Formulations et méthodes de traitement de pression intraoculaire élevée
WO2017167457A1 (fr) * 2016-04-01 2017-10-05 Pharmathen S.A. Composition pharmaceutique sans conservateur pour administration ophtalmique, contenant du bimatoprost et du timolol
WO2017182138A1 (fr) * 2016-04-19 2017-10-26 Pharmathen S.A. Compositions ophtalmiques pharmaceutiques sans conservateur
WO2021049963A1 (fr) * 2019-09-13 2021-03-18 Warszawskie Zakłady Farmaceutyczne Polfa Sa Composition pharmaceutique de bimatoprost et de timolol
WO2022096965A1 (fr) * 2020-11-04 2022-05-12 Iromed Group S.r.l. Composition ophtalmique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", 2017, PHARMACEUTICAL PRESS
BAUDOUIN ET AL.: "Preservatives in eyedrops: The good, the bad and the ugly", PROG. RETIN. EYE RES., vol. 29, 2010, pages 312 - 334, XP055616054, DOI: 10.1016/j.preteyeres.2010.03.001
HOLLO ET AL.: "Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages", DRUGS, vol. 78, no. 1, 2018, pages 39 - 64, XP093006082, DOI: 10.1007/s40265-017-0843-9
KLIMKO PG ET AL.: "Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma", BR. J. PHARMACOL, vol. 176, no. 8, 2019, pages 1051 - 1058, XP071146328, DOI: 10.1111/bph.14327
YOON ET AL.: "Ophthalmic Product Development. AAPS Advances in the Pharmaceutical Sciences Series", vol. 37, SPRINGER, article "Packaging Development: Multi-dose container closure for preservative free products, extractable/leachables from packaging, new technologies", pages: 229 - 245

Similar Documents

Publication Publication Date Title
KR101738502B1 (ko) 보레이트-폴리올 복합체를 함유하는 수성 약학 조성물
US10772830B1 (en) Preservative free pharmaceutical compositions for ophthalmic administration
Aldrich et al. Ophthalmic preparations
AU2008344909B2 (en) Ophthalmic composition comprising a prostaglandin
Kumar et al. Recent challenges and advances in ophthalmic drug delivery system
US20190076442A1 (en) Preservative free pharmaceutical composition for ophthalmic administration containing bimatoprost and timolol
EP2886130A1 (fr) Composition pharmaceutique ophtalmique et son procédé de préparation
EP3445331B1 (fr) Compositions ophtalmiques pharmaceutiques sans conservateur
CA3124945A1 (fr) Compositions pharmaceutiques ophtalmiques et procedes de traitement d'une maladie de surface oculaire
US20210128458A1 (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
IL293859A (en) Ophthalmic preparations that include d2o
WO2024003078A1 (fr) Composition ophtalmique sans conservateur comprenant un analogue de prostaglandine
WO2024018090A1 (fr) Composition ophtalmique sans conservateur comprenant un agent anti-glaucome
JP2008120764A (ja) プロスタグランジン水性点眼剤
KR102277168B1 (ko) 구토 유발을 위한 수의학적 방법
US20230218627A1 (en) Preservative free pharmaceutical composition for ophthalmic administration comprising brimonidine
JP7037349B2 (ja) 水溶性粘稠化剤を含有する医薬組成物
US20220378698A1 (en) Preservative free pharmaceutical composition for ophthalmic administration containing cyclosporine
US20220323448A1 (en) Compositions and methods for treating eyes and methods of preparation
US20230181460A1 (en) Preservative free pharmaceutical composition for ophthalmic administration containing cyclosporine
EP4088713A1 (fr) Composition pharmaceutique ophtalmique comprenant de l'atropine
US20230277557A1 (en) Pharmaceutical kits and their use for treating dry eye disease
WO2019131517A1 (fr) Produit ophtalmique et procédé de masquage
WO2022076398A1 (fr) Kits pharmaceutiques et leur utilisation pour traiter le syndrome de l'oeil sec
GB2597411A (en) Compositions and methods for treating presbyopia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23735739

Country of ref document: EP

Kind code of ref document: A1